FDA Asks Feedback on Tobacco Seller Training Info
Published Date: 2/25/2026
Notice
Summary
The FDA is asking for public feedback on their plan to keep collecting info about tobacco retailer training programs. These programs help stores teach employees the rules about selling tobacco safely and legally. If approved, this will continue without extra costs but keep the training standards clear and up-to-date. Comments are due by March 27, 2026, so retailers and the public can weigh in!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Time burden for retailer training records
The FDA estimates 237,113 retail establishments keep records for tobacco retailer training programs each year. FDA estimates one-time development for newly creating programs (18,969 establishments) totals 474,225 hours (25 hours per respondent for development activities) and annual recordkeeping totals 569,071 hours across establishments; FDA reports the total estimated annual hours changed from 2,183,780 to 1,043,296 hours, a decrease of 1,140,484 hours.
Guidance recommends tests, annual refreshers, 4-year records
FDA's guidance recommends retailers train employees on Federal tobacco sale rules, age verification, refusals, and other topics; require a written test before selling tobacco; provide refresher training at least annually; conduct internal compliance checks every 6 months; and retain training records for 4 years so they can show evidence during the 48-month civil money penalty period. Commenters and FDA say these recommendations are linked to preventing youth access to tobacco products.
Program remains voluntary; no FDA approvals now
FDA states the Tobacco Retailer Training Programs guidance is voluntary: retailers are not required to implement programs or submit them to FDA, and FDA will not recognize or approve existing training programs or certifications because it has not promulgated regulations establishing approved programs. FDA also states there are no capital or operating and maintenance costs associated with this information collection.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03770 — Noise Exposure Map Notice: Louisville Muhammad Ali International Airport (SDF)
The FAA has officially approved the noise maps for Louisville Muhammad Ali International Airport, showing current and future noise levels around the airport. This means local communities and officials now have a clear picture of noise impact, helping guide future plans to keep neighborhoods peaceful. The approval took effect on February 23, 2026, and could lead to new steps to reduce noise and protect residents.
Next: 2026-03772 — Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice Regulations for Medicated Feeds
The FDA wants feedback on how medicated animal feed makers keep their records to make sure everything’s safe and up to date. This affects companies that produce medicated feeds, and they have until April 27, 2026, to share their thoughts. No big money changes yet, just a chance to improve how info is collected and stored.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in